Turner Pope Investments (TPI) is delighted to introduce a forthcoming AIM IPO: Intuitive Investments Group plc (“IIG”). The principal behind IIG might not, however, need any introduction as David Evans has time and again proven himself an astute stock-picker and operator in the Life Sciences sector for over 25 years.
TPI has helped to structure a public vehicle to provide investors access to David’s intuition; the guiding force behind many of his investments to date and the philosophy on which IIG is built. David will be leading the fundraise for IIG with a large personal capital commitment so will have a lot more riding on the Company’s success than reputation alone.
•TPI is sole bookrunner and broker
•An opportunity to invest alongside legendary life sciences entrepreneur David Evans
•David Evans is personally investing £1m, no discounted founder shares, TPI clients are invited to invest on the same terms
David has been involved in both private and public companies, through investments as well as serving as a senior director of many, including facilitating twelve companies’ transition to being publicly traded, leading many M&A transactions as well as overseeing four successful exits.
He was a key member of the team that floated Shield Diagnostics in 1993, later becoming CEO and was responsible for the merger with Axis Biochemicals to create Axis-Shield plc, which was sold in 2011 for £235m. David has served on the board of a number of other quoted Life Sciences companies, including Collagen Solutions plc, Omega Diagnostics Group plc, Genedrive plc, Premaitha Health plc (now Yourgene Health plc), OptiBiotix Health plc, Venn Life Sciences plc (now Open Orphan plc), EKF Diagnostics Holdings plc, Scancell Holdings plc, Immunodiagnostic Systems Holdings plc, BBI Holdings plc (now BBI Diagnostics Group Limited) and Horizon Discovery plc.
At IIG, he will be assisted by experienced non-execs in: Malcolm Gillies, a lawyer by background with a number of director roles with Life Science focused public companies; Cormac Kilty, a founder of a number of Life Science and Diagnostics companies; and Colin Willis, a venture capital specialist with over 24 years of experience in the field including at 3i. In addition, the Board can call upon the knowledge and contacts of an extensive Advisory Panel that includes: Dr. Stewart White, who has acted as Chairman and CEO of numerous Life Science companies; Julian Banes, CEO of EKF Diagnostics; Ron Long, who has held a number of positions as CEO and Chairman of Life Science companies; Per Matsson, who has experience in senior positions in various Life Science R&D departments; and Alistair Smith, CEO of Avacta Group.
We believe the Board and Advisory Panel combined experience will translate to a high level of industry contacts, deal flow and insight to provide investors with a series of opportunities that might otherwise not be available to them in the ordinary course, but which could provide extraordinary returns.
The minimum raise will be £7.5m of which a significant proportion is coming from the Board and associates.
Please click on this link to see coverage of the deal in today’s edition of The Times.
